Insmed Announces Proposed $500 Million Public Offering of Common Stock

Core Viewpoint - Insmed Incorporated plans to offer and sell $500 million of its common stock in an underwritten public offering, with an option for underwriters to purchase an additional 15% of the shares [1] Company Overview - Insmed Incorporated is a global biopharmaceutical company focused on transforming the lives of patients with serious and rare diseases [5] - The company's first commercial product is a first-in-disease therapy approved in the U.S., Europe, and Japan for a chronic lung disease [5] - Insmed is advancing a pipeline of investigational therapies targeting serious unmet needs, including inflammatory diseases and rare pulmonary disorders [5] - The company is also engaged in early-stage research involving technologies such as artificial intelligence-driven protein engineering and gene therapy [5] Offering Details - The public offering is being conducted under Insmed's shelf registration statement on Form S-3, which became effective on May 19, 2023 [3] - Goldman Sachs & Co. LLC and Leerink Partners are serving as joint book-running managers for the offering [2] - A preliminary prospectus supplement will be filed with the SEC and will be available on the SEC's website [3]